Competitive intelligence on
small-molecule drugs and
the 80,000 global patents
covering them

Start your free trial now

No commitment — No credit card required

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: STALEVO 150

« Back to Dashboard

Summary for Tradename: STALEVO 150

Patents:3
Applicants:1
NDAs:1
Suppliers: see list6

Clinical Trials for: STALEVO 150

Levodopa Concentration Profile With Stalevo 75/125 mg
Status: Completed Condition: Parkinson's Disease

Study to Evaluate Initiation of Stalevo in Early Wearing-Off
Status: Completed Condition: Parkinson's Disease

Stalevo in Early Wearing-Off Patients
Status: Completed Condition: Idiopathic Parkinson's Disease

Pharmacokinetic Study With Repeated Doses of Stalevo
Status: Completed Condition: Pharmacokinetics

PET-Study: Effects of Single Doses of Stalevo and Levodopa/Carbidopa on Striatal 11C-Raclopride Binding
Status: Terminated Condition: ParkinsonĀ“s Disease

Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor Fluctuations
Status: Completed Condition: Parkinson's Disease

Adherence of Stalevo, Entacapone and Levodopa
Status: Completed Condition: Parkinson's Disease

Comparing Different Levodopa/Carbidopa/Entacapone Treatment Regimens
Status: Completed Condition: Parkinson's Disease

An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN)
Status: Completed Condition: Parkinson's Disease

Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy
Status: Completed Condition: Parkinson's Disease

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Orion Pharma
STALEVO 150
carbidopa; entacapone; levodopa
TABLET;ORAL021485Jun 11, 2003RXNo6,500,867<disabled>Y<disabled>
Orion Pharma
STALEVO 150
carbidopa; entacapone; levodopa
TABLET;ORAL021485Jun 11, 2003RXNo5,446,194<disabled>Y<disabled>
Orion Pharma
STALEVO 150
carbidopa; entacapone; levodopa
TABLET;ORAL021485Jun 11, 2003RXNo6,797,732<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access , or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: STALEVO 150

Drugname Dosage Strength RLD Submissiondate
carbidopa, levodopa and entacaponeTablets25/100/200 mg and 37.5/150/200 mgStalevo 1506/29/2007
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc